THE INFORMED PATIENT*

1 Lind J. A treatise of the scurvy. In three parts. Edinburgh; A Kincaid &A Donaldson; 1753.

2 Phelps H , editor. An Essex Christmas. Stroud; Alan Sutton Publishing Limited; 1993.

3Special theme issue. From compliance to concordance. BMJ 2003; 326(7419).

4 Smith R. Editor’s choice; the screening industry. BMJ 2003; 326.

5 Swensen SJ. Screening for cancer with computed tomography. BMJ 2003; 326:894-5.

6 Lewis DK J Robinson Wilkinson E. Factors involved in deciding to start preventive treatment; qualitative study of clinicians’ and lay people’s attitudes. BMJ 2003; 327:841.

7 Laurance J. HRT: the new thalidomide. Independent 4 October 2003; 1.

8 Leaman R. Letter. Independent 6 October 2003, Letters page.

9Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003; 362:419-27.

10 Grice A. Middle classes work the NHS system, says Reid. Independent 27 June 2003; 8.

11NHS must give free information, says draft guidance from NICE. CancerBACUP News Autumn 2003; Issue 48.

12 Moynihan R I Heath Henry D. Selling sickness; the pharmaceutical industry and disease mongering. BMJ 2002; 324:886-91.

13 Lerner BH. The breast cancer wars: fear, hope and the pursuit of a cure in twentieth-century America. New York; Oxford University Press; 2003.

14 Kushner R. Breast cancer: a personal and investigative report. New York; Harcourt Brace Jovanovitch; 1975.

15http;//www.breastcancercare.org.uk

16http;//www.cancerbacup.org.uk

17 Forstater M. The spiritual teachings of Marcus Aurelius. Part I: what is the right way to live? London; Hodder and Stoughton; 2000.

18Rig Veda;‘Look to this day’ c. 1,500 BC.

19Refractor. Uncertainty. Lancet 2001; 358(9298):2090.

20Refractor. Knowledge management. Lancet 2000; 356 (9242): 1692.

21 Thornton H. Information and involvement. Health Expect 2001; 4(1):71-4

22 Stewart DC. Draft ideas for learning from Lind’s controlled trial. In; Chalmers I, Milne I, Tröhler U, editors. The James Lind Library (www.jameslindlibrary.org). Accessed 9 November 2003.

23Special theme issue. Communicating risks; illusion or truth? BMJ 2003; 327(7417).

24 Edwards A E Elwyn Atwell C Shared decision making and risk communication in general practice - a study incorporating systematic literature review, psychometric evaluation of outcome measures, and quantitative, qualitative and health economic analysis of a cluster randomised trial of professional skill development. Report to Health in Partnership programme, UK Department of Health. (http;//www.healthinpartnership.org/studies/edwards.html). Cardiff; Department of General Practice, University of Wales College of Medicine; 2002.

25 Thornton HM. Breast cancer trials; a patient’s viewpoint. Lancet 1992; 339:44-5.

26 Hochhauser M. Risk communication; consent delayed is consent denied. (http;//bmj.bmjjournals.com/cgi/eletters/327/7417/731538336) Accessed 23 October 2003.

27Editorial; The globalisation of the NHS. Lancet 2002; 3S9: 1447-8.

28IBIS Investigators. IBIS-II: an international multicentre study of anastrozole vs placebo in postmenopausal women at increased risk of breast cancer, and of anastrozole vs tamoxifen in postmenopausal women with ER+ve ductal carcinoma in situ (DCIS). Current National Trials. London; National Cancer Research Institute; 2002.

29 Laurance J. Hailed as the biggest advance in decades, can this drug prevent 70% of breast cancers? Independent 1 October 2003; 3.

30 Patnick J. Screens for survival. Chemistry and Industry, 6 October 2003; 19:17.

31 Patnick J. Letter. Women need better information on routine mammography; women’s needs inform contents of screening literature. BMJ 2003; 327:868-9.

32General Medical Council. Seeking patients’ consent: the ethical considerations. London; General Medical Council; November 1998.

33 Cuzick J. Personal communication. 2003.

34 Thornton H. Questions about anastrozole for early breast cancer. Lancet 2002; 360: 1890.

35 Thornton H. Anastrozole as a preventive agent in breast cancer. Lancet 2003; 362: 1911—12.

36 Cuzick J C O'Neill Howell A Anastrolzole for ductal carcinoma in situ. Lancet 2003; 362:832.

37 Lock S. Britain prefers talk to action. Which is why it has failed to tackle research misconduct. BMJ 2003; 327:940-1.

38 Thornton H A Edwards Baum M. Women need better information about routine mammography. BMJ 2003; 327: 101-3.

39 Thornton H. Pairing accountability with responsibility -the consequences of screening ‘promotion’. Med Sci Monit 2001; 7(3):531-3.

40 Davey C V White Ward JE. Insurance repercussions of mammographic screening; what do women think? Med Sci Monit 2003; 8:44-5.

41 Rakovitch E E Franssen Kims J A comparison of risk perception and psychological morbidity in women with ductal carcinoma in situ and early breast cancer. Breast Cancer Research and Treatment 2003; 77:285-93.

42NHS Breast Screening Programme. Breast screening: the facts 2001. (http;//www.cancerscreening.nhs.uk/breasts creen/publications/ia-02.html) Accessed 13 March 2004.

43 Laurance J. Health warning; screening can seriously damage patients. Independent,” July 2003; 3.

44 Baum M Thornton H. Women’s advocacy groups and research in breast cancer. The Breast 2001; 10(Suppl. 3): 19-22.

45 Gigerenzer G. Reckoning with risk: learning to live with uncertainty. London: Penguin Books; 2001.

46Op. cit ref. 23.

47 Thornton H A Edwards Elwyn G. Evolving the multiple roles of “patients” in health-care research; reflections after involvement in a trial of shared decision-making. Health Expect 2003; 6: 189-97.

48 Sacks J. The politics of hope. London: Jonathan Cape; 1997;177.

49Medical Research Council. Clinical trials for tomorrow. An MRC review of randomised controlled trials. London; MRC Clinical Trials Series; 2003.

50 Sacks J. The dignity of difference. How to avoid the clash of civilisations. London; Continuum; 2003; 106-8.